Oral therapy for chronic immune thrombocytopenic purpura

Revolade (eltrombopag) is the first oral treatment option for chronic immune thrombocytopenic purpura to be launched in the UK.

Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes.

The dosing schedule is dependent on the individual patient's platelet counts but consists of a once daily oral dose.

The objective of treatment with eltrombopag is to maintain platelet counts above the level for haemorrhagic risk (50000/microlitre).

In most patients, measurable elevations in platelet counts take 1-2 weeks.

View Revolade drug record

Further information: GSK

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more